Renalytix PLC
LSE:RENX

Watchlist Manager
Renalytix PLC Logo
Renalytix PLC
LSE:RENX
Watchlist
Price: 10.75 GBX 7.93% Market Closed
Market Cap: 35.6m GBX
Have any thoughts about
Renalytix PLC?
Write Note

Renalytix PLC
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Renalytix PLC
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Renalytix PLC
LSE:RENX
Operating Income
-$42.4m
CAGR 3-Years
-56%
CAGR 5-Years
-251%
CAGR 10-Years
N/A
Craneware PLC
LSE:CRW
Operating Income
$21.5m
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
7%
Cambridge Cognition Holdings PLC
LSE:COG
Operating Income
-ÂŁ67k
CAGR 3-Years
21%
CAGR 5-Years
50%
CAGR 10-Years
27%
Intelligent Ultrasound Group PLC
LSE:IUG
Operating Income
-ÂŁ1.8m
CAGR 3-Years
27%
CAGR 5-Years
15%
CAGR 10-Years
N/A
EMIS Group PLC
LSE:EMIS
Operating Income
ÂŁ38.6m
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
5%
Doctor Care Anywhere Group PLC
ASX:DOC
Operating Income
-ÂŁ8.4m
CAGR 3-Years
1%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
No Stocks Found

Renalytix PLC
Glance View

Market Cap
35.6m GBX
Industry
Health Care

Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.

RENX Intrinsic Value
14.29 GBX
Undervaluation 25%
Intrinsic Value
Price

See Also

What is Renalytix PLC's Operating Income?
Operating Income
-42.4m USD

Based on the financial report for Jun 30, 2023, Renalytix PLC's Operating Income amounts to -42.4m USD.

What is Renalytix PLC's Operating Income growth rate?
Operating Income CAGR 5Y
-251%

Over the last year, the Operating Income growth was 26%. The average annual Operating Income growth rates for Renalytix PLC have been -56% over the past three years , -251% over the past five years .

Back to Top